Neurocrine Biosciences, Inc. (NBIX) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day everyone and welcome to today's NeuroKrin Biosciences Second Quarter 2025 Results Conference. At this time all participants are in a listen-only mode. Later you will have the opportunity to ask questions during the question and answer session. You may register to ask a question at any time by pressing star 1 on your telephone keypad. You may withdraw yourself from the queue by pressing star 2. Please note this call may be recorded and I will be standing by if you should need any assistance. It is now my pleasure to turn the conference over to Vice President of Investor Relations, Todd Tuschla. Please go ahead sir. Thank you and happy Wednesday everyone. Welcome to NeuroKrin Biosciences Second Quarter 2025 Earnings Call. With me today are Kyle Gano, Chief Executive Officer, Matt Abernathy, Chief Financial Officer, Eric Benovitch, Chief Commercial Officer, Ivy Roberts, and for one first time as Chief Medical Officer Sanjay Keswani. During today's call we will be making forward-looking statements. These statements are subject to certain risks and uncertainties and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. After prepared remarks we will jump into Q&A. I now turn the call over to Kyle. Thank you Todd. Good afternoon everyone. We were especially pleased with our standout second quarter that delivered high double-digit growth, which showcased our diversified revenue profile and highlighted the organization's ongoing evolution. From a commercial perspective our Ingresa-based business continues to post solid growth and we are excited by the strong early performance of Krenesiti. For Ingresa, our strategic investments to enhance payer access led to another record of new patient starts and ...